James Chih-Hsin Yang
0000-0002-5586-5138
National Taiwan university hospital
8 papers found
Refreshing results…
Phase II study to determine the anti-tumor activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in esophageal cancer
Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non–Small-Cell Lung Cancer: Results From LASER301
Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET-Amplified Non–Small Cell Lung Cancer: TATTON
Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer
A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non–Small-Cell Lung Cancer
Meta-Analysis of First-Line Pemetrexed plus Platinum Treatment in Comparison with Other Platinum Based Doublet Regimens in Elderly East Asian Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer
Missing publications? Search for publications with a matching author name.